10-Q · May 15, 2026
NRx Pharmaceuticals reported Q1 2026 revenue of approximately $1.1 million, primarily from the clinical services provided post-acquisition of Dura. Net loss for the quarter was reduced to $1.4 million from $5.5 million…
Earnings analysis · 10-Q
NRXP earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q excerpt is principally compliance and other-information content and does not include the financial statements, MD&A, balance sheet, cash flow statement, or segment data needed to assess quarterly…
Read full summary
The supplied 10-Q excerpt is principally compliance and other-information content and does not include the financial statements, MD&A, balance sheet, cash flow statement, or segment data needed to assess quarterly operating trends. Controls were deemed effective as of June 30, 2026, with no unregistered equity sales or senior-security defaults during the three and six months ended that date. No material risk-factor changes were reported versus the 2025 Form 10-K, and no quantitative guidance was provided in the supplied text.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Controls deemed effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, providing reasonable assurance over required disclosures.
-
Financial reporting controls effective
Management concluded that internal control over financial reporting was effective as of June 30, 2026, under the COSO 2013 framework.
-
No unregistered equity sales
The company reported no unregistered sales of equity securities during the three and six months ended June 30, 2026 that had not been previously reported.
-
No senior-security defaults
The company reported no defaults upon senior securities during the three and six months ended June 30, 2026 that had not been previously reported.
-
No insider trading-plan changes
No directors or executive officers adopted or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the three and six months ended June 30, 2026.
What to watch
-
Existing 10-K risks remain applicable
The company stated that there were no material changes to the risk factors disclosed in its 2025 Form 10-K, filed March 23, 2026. Existing risks therefore remain applicable despite no identified update in this 10-Q.
-
Residual control risk remains
Internal controls provide only reasonable assurance and may be circumvented through collusion or management override; management nevertheless assessed controls as effective as of June 30, 2026.
-
Legal-proceeding exposure unclear
The filing directs investors to Note 10 for certain legal proceedings as of and for the six months ended June 30, 2026, but the supplied excerpt does not provide the nature or potential exposure of those proceedings.
Management's outlook
No quantitative revenue or EPS outlook was provided in the supplied 10-Q text; outlook may be addressed in a separate earnings release or conference call.
Earlier filings 4
10-K · March 23, 2026
NRx Pharmaceuticals reported a fourth quarter revenue of $983,000, significantly below consensus estimates of $7.03 million while achieving an EPS of $0.20, beating expectations of -$0.08. The company continues to…
10-Q · November 14, 2025
NRX Pharmaceuticals reported disappointing results for Q3 2025, with revenues falling drastically short of expectations. Actual revenue was only $242,000 compared to an estimated $10.85 million, and reported EPS was…
10-Q · August 18, 2025
NRx Pharmaceuticals reported Q2 2025 results with an EPS of -$0.98, significantly missing the consensus estimate of -$0.23 and maintaining zero revenue. The company posted a net loss of $17.6 million, a drastic increase…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.